Having considered these caveats, the Yang paper [3] addresses the possibility that protein degradation is at the heart of the ability of parkin to protect cells. The protective effect of Parkin expression on pael-r toxicity is mediated by promoting pael-r degradation, but Parkin-mediated protection against mutant α α-synuclein does not involve a decrease in α α-synuclein levels. This finding agrees with previous results from in vitro studies, where α α-synuclein levels were not affected by proteasome inhibitors or expression of Parkin [4] . Therefore, Parkin is not neuroprotective because it ubiquitylates and promotes the bulk degradation of α α-synuclein, but we know that the ubiquitinligase activity of Parkin is required as recessive mutations are not neuroprotective [4] . Is it a paradox to say that Parkin protects against a protein that it doesn't degrade? I think there are two likely explanations. The simpler of the two is that there is a species of α α-synuclein that mediates toxicity and is degraded by Parkin but is difficult to detect in cultured cells or in Drosophila. A candidate is a glycosylated form of α α-synuclein that is present in human brain, sp22 [12] . To date, sp22 has not been identified in any other system and it is clear that this is a low abundance species. Until this species is detected in a system where its formation can be prevented, we cannot test whether this is how Parkin protects neurons. A more complex, but perhaps more plausible, explanation is that Parkin protects against α α-synuclein toxicity because α α-synuclein promotes
Parkin and Ubiquitylation
The question arises as to how loss of parkin function produces a disease with neuronal cell loss in selected brain regions, or, restating the problem, how Parkin normally protects cells from damaging events. It is of interest that Parkin may interact with membrane proteins, such as CASK, and be present at synapses [9] , thus implying a link to some neuron-specific function. At one level the answer would appear simple: the disease results from insufficient enzymatic activity. If adding chains of ubiquitin molecules (ubiquitylation) to a target protein promotes degradation via the proteasome (Figure 1) , then one might fairly assume that the role of Parkin is to control the steady-state levels of otherwise damaging proteins. But the answer is complicated by several factors.
Firstly, there are large numbers of E3 ubiquitinprotein ligases that control the ubiquitylation of target proteins. The ubiquitylation machinery therefore has a degree of redundancy, possibly allowing other E3 ligases to control protein levels when Parkin is absent. For example, one Parkin substrate, cyclin E, can be targeted for destruction by other modular E3 enzymes [10] . Secondly, Parkin has been reported to target multiple substrates, and hence it is not clear whether the effects of loss of E3 ligase activity would mean the accumulation of a specific substrate or a series of substrates. Thirdly, ubiquitylation can subserve many other functions within cells including modulation of transcription, sorting of proteins into different cellular compartments and synaptic development. However, Parkin interacts directly with the proteasome [11] , suggesting that protein degradation is in fact a key activity for Parkin. There are also a number of ubiquitin-like molecules that may play similar roles to ubiquitin in different protein regulation pathways, although Parkin activity is so far only known to be directed towards ubiquitin itself.
Having considered these caveats, the Yang paper [3] addresses the possibility that protein degradation is at the heart of the ability of parkin to protect cells. The protective effect of Parkin expression on pael-r toxicity is mediated by promoting pael-r degradation, but Parkin-mediated protection against mutant α α-synuclein does not involve a decrease in α α-synuclein levels. This finding agrees with previous results from in vitro studies, where α α-synuclein levels were not affected by proteasome inhibitors or expression of Parkin [4] . Therefore, Parkin is not neuroprotective because it ubiquitylates and promotes the bulk degradation of α α-synuclein, but we know that the ubiquitinligase activity of Parkin is required as recessive mutations are not neuroprotective [4] . Is it a paradox to say that Parkin protects against a protein that it doesn't degrade? I think there are two likely explanations. The simpler of the two is that there is a species of α α-synuclein that mediates toxicity and is degraded by Parkin but is difficult to detect in cultured cells or in Drosophila. A candidate is a glycosylated form of α α-synuclein that is present in human brain, sp22 [12] . To date, sp22 has not been identified in any other system and it is clear that this is a low abundance species. Until this species is detected in a system where its formation can be prevented, we cannot test whether this is how Parkin protects neurons. A more complex, but perhaps more plausible, explanation is that Parkin protects against α α-synuclein toxicity because α α-synuclein promotes cellular damage via the same proteins that Parkin normally degrades.
Protein Aggregation and Degradation Pathways
There are several ways in which degradation of one or more substrates may prevent α α-synuclein toxicity. If there are multiple proteins that are each marginally damaging to cells, then the additive effect of reducing levels of each may be beneficial. Proteins such as pael-r used in the recent Drosophila experiments that are directly toxic at high levels may cause neuronal damage via ER stress (although it should be noted that not all groups have been able to replicate the protective actions of Parkin in this model [8] ). A more interesting possibility is that a lack of Parkin activity might cause the build-up of the total protein content in vulnerable neurons. Increased concentration of macromolecules within the cell could induce a 'molecular crowding' phenomenon, which would promote the aggregation of α α-synuclein [13] . Several lines of evidence suggest that aggregation of α α-synuclein is toxic [14] , and both pathogenic α α-synuclein mutations favour the formation of soluble, oligomeric species [15] . Lack of Parkin activity may cause damage by promoting α α-synuclein aggregation, and increased Parkin activity may antagonize this effect.
There are several possible subcellular targets of α α-synuclein toxicity, including mitochondria, synaptic vesicles and the proteasome itself. We could view ER stress, ceramide or proteasome inhibitors as ways in which to mimic the toxic effects of α α-synuclein. For example, if α α-synuclein toxicity includes damage to mitochondria (see [16] ) then the ability of Parkin to protect against ceramide-induced mitochondrial apoptosis [8] may be related to this. Flies lacking parkin expression also show mitochondrial damage [17] .
All of these results suggest that Parkin has a generally neuroprotective effect that manifests itself in dopaminergic neurons in the disease. Perhaps this indicates a therapeutic opportunity for PD. If parkin has such widespread utility, then molecules that promote parkin expression or enhance its activity may be useful in PD patients. Although Parkin activity is not generally lacking in sporadic PD, it is still reasonable to suggest that boosting Parkin levels would be helpful. Experiments such as those performed in Drosophila suggest that Parkin levels can be manipulated without deleterious effects on the organism, demonstrating the utility and validity of experiments in model organisms as a way forward to develop new treatments for neurological diseases. 
